H.C. Wainwright Maintains Buy Rating for Syndax Pharmaceuticals Following Positive ASCO Data
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating on ASCO data
Image: Investing Australia
H.C. Wainwright has reaffirmed a Buy rating and a $40 price target for Syndax Pharmaceuticals after the company presented promising data on Revuforj at the ASCO 2026 conference. The stock currently trades at $18.39, with analysts optimistic about its potential growth.
- 01Syndax Pharmaceuticals' stock is currently priced at $18.39, with analyst price targets ranging from $29 to $57.
- 02The ASCO presentation included data from 24 patients, showing a 90% two-year overall survival rate compared to 51% in a historical cohort.
- 0329% of patients remained on Revuforj therapy at the last follow-up, with a median duration of treatment of 10 months.
- 04Stifel raised its price target for Syndax shares to $46 while maintaining a Buy rating, despite the company missing first-quarter sales estimates.
- 05The positive clinical outcomes presented at ASCO are expected to enhance investor confidence and analyst earnings forecasts.
Advertisement
In-Article Ad
H.C. Wainwright has reiterated a Buy rating and set a price target of $40.00 for Syndax Pharmaceuticals (NASDAQ:SNDX) following the company's oral presentation at the American Society of Clinical Oncology (ASCO) 2026 conference. Currently trading at $18.39, the stock has analyst targets ranging from $29 to $57, indicating potential undervaluation. The ASCO presentation detailed the outcomes of 24 patients treated with Revuforj post-hematopoietic stem cell transplantation (HSCT), revealing a 90% overall survival rate over two years, significantly higher than the 51% rate in a historical cohort. The treatment duration averaged 10 months, with 29% of patients still on therapy at the last follow-up. Despite missing consensus sales estimates for Revuforj/Niktimvo in Q1 of fiscal 2026, Stifel has raised its price target to $46, citing optimism about the drug's future trajectory. The data presented at ASCO highlighted improved relapse rates in patients with specific genetic subtypes of acute leukemia, further bolstering analyst confidence.
Advertisement
In-Article Ad
The positive clinical data from ASCO is likely to influence investor sentiment and potentially lead to increased funding for Syndax Pharmaceuticals.
Advertisement
In-Article Ad
Reader Poll
What do you think about the future of Syndax Pharmaceuticals after the ASCO presentation?
Connecting to poll...
More about H.C. Wainwright
H.C. Wainwright ने Upstream Bio को Buy रेटिंग दी, प्राइस टारगेट $36
Investing भारत • Jun 3, 2026
OrbiMed invierte 15 millones de dólares en acciones de Q32 Bio
Investing • Jun 2, 2026
Jefferies maintient son avis sur Mineralys alors que des spéculations sur des acquisitions émergent
Investing French • Jun 2, 2026
Read the original article
Visit the source for the complete story.